01:03 PM EDT, 06/02/2025 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) on Monday reported long-term survival results from a phase 2 trial evaluating its investigational HER2-targeted therapy Ziihera in combination with chemotherapy as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma.

The company said median overall survival reached 36.5 months among the 46 enrolled patients, with a median progression-free survival of 12.5 months. In the subgroup of 41 patients with centrally confirmed HER2-positive tumors, median progression-free survival was 15.2 months.

The data was presented at the American Society of Clinical Oncology annual meeting.

A Phase 3 trial evaluating Ziihera in the same indication is ongoing, with top-line results expected in the second half of 2025, Jazz said.

Price: 108.84, Change: +0.77, Percent Change: +0.71